ciprofloxacin has been researched along with clonidine in 21 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 10 (47.62) | 29.6817 |
| 2010's | 8 (38.10) | 24.3611 |
| 2020's | 3 (14.29) | 2.80 |
| Authors | Studies |
|---|---|
| Carrupt, PA; Crivori, P; Cruciani, G; Testa, B | 1 |
| Alvarez-Pedraglio, A; Colmenarejo, G; Lavandera, JL | 1 |
| Benz, RD; Contrera, JF; Kruhlak, NL; Matthews, EJ; Weaver, JL | 1 |
| Andricopulo, AD; Moda, TL; Montanari, CA | 1 |
| Lombardo, F; Obach, RS; Waters, NJ | 1 |
| Chupka, J; El-Kattan, A; Feng, B; Miller, HR; Obach, RS; Troutman, MD; Varma, MV | 1 |
| Chen, L; He, Z; Li, H; Liu, J; Liu, X; Sui, X; Sun, J; Wang, Y; Zhang, W | 1 |
| Barnes, JC; Bradley, P; Day, NC; Fourches, D; Reed, JZ; Tropsha, A | 1 |
| Campillo, NE; Guerra, A; Páez, JA | 1 |
| Annand, R; Gozalbes, R; Jacewicz, M; Pineda-Lucena, A; Tsaioun, K | 1 |
| Chen, M; Fang, H; Liu, Z; Shi, Q; Tong, W; Vijay, V | 1 |
| Chen, M; Hu, C; Suzuki, A; Thakkar, S; Tong, W; Yu, K | 1 |
| Jones, LH; Nadanaciva, S; Rana, P; Will, Y | 1 |
| Backman, JT; Granfors, MT; Neuvonen, M; Neuvonen, PJ | 1 |
| Homma, M; Kohda, Y; Momo, K; Ohkoshi, N; Tamaoka, A; Yoshizawa, T | 1 |
| Henney, HR; Runyan, JD | 1 |
| Abd-Elsayed, A; Elsharkawy, H; Sakr, W | 1 |
| Curkovic, I; Egbring, M; Jödicke, AM; Kullak-Ublick, GA; Neuer, T; Roos, M; Tomka, IT; Zellweger, U | 1 |
| Burden, A; Dahmke, H; Kupferschmidt, H; Rudolph, A; Weiler, S | 1 |
| Giannouchos, TV; Gómez-Lumbreras, A; Malone, DC | 1 |
| Boyce, RD; Gómez-Lumbreras, A; Horn, J; Malone, DC; Tan, MS; Villa-Zapata, L | 1 |
2 review(s) available for ciprofloxacin and clonidine
| Article | Year |
|---|---|
DILIrank: the largest reference drug list ranked by the risk for developing drug-induced liver injury in humans.
Topics: Chemical and Drug Induced Liver Injury; Databases, Factual; Drug Labeling; Humans; Pharmaceutical Preparations; Risk | 2016 |
A clinically relevant review of tizanidine hydrochloride dose relationships to pharmacokinetics, drug safety and effectiveness in healthy subjects and patients.
Topics: Chemistry, Pharmaceutical; Ciprofloxacin; Clonidine; Dose-Response Relationship, Drug; Drug Interactions; Fluvoxamine; Humans; Multiple Sclerosis; Muscle Relaxants, Central; Treatment Outcome | 2008 |
1 trial(s) available for ciprofloxacin and clonidine
| Article | Year |
|---|---|
Ciprofloxacin greatly increases concentrations and hypotensive effect of tizanidine by inhibiting its cytochrome P450 1A2-mediated presystemic metabolism.
Topics: Adult; Anti-Infective Agents; Area Under Curve; Blood Pressure; Caffeine; Chromatography, High Pressure Liquid; Ciprofloxacin; Clonidine; Cytochrome P-450 CYP1A2 Inhibitors; Enzyme Inhibitors; Half-Life; Heart Rate; Humans; Muscle Relaxants, Central; Phosphodiesterase Inhibitors | 2004 |
18 other study(ies) available for ciprofloxacin and clonidine
| Article | Year |
|---|---|
Predicting blood-brain barrier permeation from three-dimensional molecular structure.
Topics: Blood-Brain Barrier; Databases, Factual; Models, Chemical; Molecular Conformation; Multivariate Analysis; Permeability; Pharmaceutical Preparations; Pharmacokinetics; Structure-Activity Relationship | 2000 |
Cheminformatic models to predict binding affinities to human serum albumin.
Topics: Adrenergic beta-Antagonists; Antidepressive Agents, Tricyclic; Chromatography, Affinity; Cyclooxygenase Inhibitors; Databases, Factual; Humans; Hydrophobic and Hydrophilic Interactions; Penicillins; Pharmaceutical Preparations; Protein Binding; Quantitative Structure-Activity Relationship; Reproducibility of Results; Serum Albumin; Steroids | 2001 |
Assessment of the health effects of chemicals in humans: II. Construction of an adverse effects database for QSAR modeling.
Topics: Adverse Drug Reaction Reporting Systems; Artificial Intelligence; Computers; Databases, Factual; Drug Prescriptions; Drug-Related Side Effects and Adverse Reactions; Endpoint Determination; Models, Molecular; Quantitative Structure-Activity Relationship; Software; United States; United States Food and Drug Administration | 2004 |
Hologram QSAR model for the prediction of human oral bioavailability.
Topics: Administration, Oral; Biological Availability; Holography; Humans; Models, Biological; Models, Molecular; Molecular Structure; Pharmaceutical Preparations; Pharmacokinetics; Quantitative Structure-Activity Relationship | 2007 |
Trend analysis of a database of intravenous pharmacokinetic parameters in humans for 670 drug compounds.
Topics: Blood Proteins; Half-Life; Humans; Hydrogen Bonding; Infusions, Intravenous; Pharmacokinetics; Protein Binding | 2008 |
Physicochemical determinants of human renal clearance.
Topics: Humans; Hydrogen Bonding; Hydrogen-Ion Concentration; Hydrophobic and Hydrophilic Interactions; Kidney; Metabolic Clearance Rate; Molecular Weight | 2009 |
Prediction of volume of distribution values in human using immobilized artificial membrane partitioning coefficients, the fraction of compound ionized and plasma protein binding data.
Topics: Blood Proteins; Chemistry, Physical; Computer Simulation; Humans; Membranes, Artificial; Models, Biological; Pharmaceutical Preparations; Protein Binding; Tissue Distribution | 2009 |
Cheminformatics analysis of assertions mined from literature that describe drug-induced liver injury in different species.
Topics: Animals; Chemical and Drug Induced Liver Injury; Cluster Analysis; Databases, Factual; Humans; MEDLINE; Mice; Models, Chemical; Molecular Conformation; Quantitative Structure-Activity Relationship | 2010 |
Neural computational prediction of oral drug absorption based on CODES 2D descriptors.
Topics: Administration, Oral; Humans; Models, Chemical; Neural Networks, Computer; Permeability; Quantitative Structure-Activity Relationship; Technology, Pharmaceutical | 2010 |
QSAR-based permeability model for drug-like compounds.
Topics: Caco-2 Cells; Cell Membrane Permeability; Drug Discovery; Humans; Pharmaceutical Preparations; Pharmacokinetics; Quantitative Structure-Activity Relationship | 2011 |
FDA-approved drug labeling for the study of drug-induced liver injury.
Topics: Animals; Benchmarking; Biomarkers, Pharmacological; Chemical and Drug Induced Liver Injury; Drug Design; Drug Labeling; Drug-Related Side Effects and Adverse Reactions; Humans; Pharmaceutical Preparations; Reproducibility of Results; United States; United States Food and Drug Administration | 2011 |
Development of a cell viability assay to assess drug metabolite structure-toxicity relationships.
Topics: Adenosine Triphosphate; Benzbromarone; Cell Line; Cell Survival; Chromans; Cytochrome P-450 CYP2C9; Cytochrome P-450 CYP2D6; Cytochrome P-450 CYP3A; Cytochrome P-450 Enzyme System; Humans; Pharmaceutical Preparations; Thiazolidinediones; Troglitazone | 2016 |
Drug interaction of tizanidine and ciprofloxacin: case report.
Topics: Blood Pressure; Ciprofloxacin; Clonidine; Drug Interactions; Female; Heart Rate; Humans; Middle Aged | 2006 |
A severe interaction between Tizanidine and Ciprofloxacin.
Topics: Anti-Bacterial Agents; Ciprofloxacin; Clonidine; Drug Interactions; Female; Humans; Middle Aged; Muscle Relaxants, Central; Severity of Illness Index | 2015 |
Analysis of Drug-Drug Interactions in Swiss Claims Data Using Tizanidine and Ciprofloxacin as a Prototypical Contraindicated Combination.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Anti-Bacterial Agents; Ciprofloxacin; Clonidine; Cohort Studies; Contraindications, Drug; Databases, Factual; Drug Interactions; Drug-Related Side Effects and Adverse Reactions; Female; Hospitalization; Humans; Insurance Claim Review; Male; Middle Aged; Patient Acceptance of Health Care; Patient Safety; Pharmacoepidemiology; Retrospective Studies; Switzerland; Young Adult | 2018 |
Coadministration of tizanidine and ciprofloxacin: a retrospective analysis of the WHO pharmacovigilance database.
Topics: Adolescent; Adrenergic alpha-2 Receptor Agonists; Adult; Aged; Aged, 80 and over; Anti-Bacterial Agents; Area Under Curve; Ciprofloxacin; Clonidine; Databases, Factual; Drug Interactions; Female; Humans; Male; Middle Aged; Pharmacovigilance; Retrospective Studies; World Health Organization; Young Adult | 2021 |
Risk of tizanidine-induced adverse events after concomitant exposure to ciprofloxacin: A cohort study in the U.S.
Topics: Ciprofloxacin; Clonidine; Cohort Studies; Drug Interactions; Female; Humans; Hypotension; Middle Aged | 2022 |
A Disproportionality Analysis of Drug-Drug Interactions of Tizanidine and CYP1A2 Inhibitors from the FDA Adverse Event Reporting System (FAERS).
Topics: Adverse Drug Reaction Reporting Systems; Ciprofloxacin; Clonidine; Cytochrome P-450 CYP1A2; Cytochrome P-450 CYP1A2 Inhibitors; Drug Interactions; Female; Fluvoxamine; Humans; Hypotension; Male; Middle Aged; United States; United States Food and Drug Administration | 2022 |